Top Markets
#1 Akedo Akedo +70.80%
#2 MEET48 MEET48 +28.68%
#3 Bitway Bitway +22.15%
#4 Astar Astar +18.51%
#5 VeThor VeThor +16.97%
#6 Falcon Finance Falcon Finance +11.18%
#7 龙虾 (Lobster) 龙虾 (Lobster) +10.89%
#8 Cross Cross +10.81%
#9 Power Protocol Power Protocol +10.32%
#10 AI Rig Complex AI Rig Complex +10.27%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rank in Stocks #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Share Price
$0.25974701
Last synced: 2025-01-06
Market Cap
$2.04M
Change (1 day)
0.74%
Change (1 year)
0.00%
Country
FR
Trade Acticor Biotech SAS (ALACT)

Category

Healthcare
Number of shares outstanding for Acticor Biotech SAS (ALACT)
Number of shares outstanding as of June 2024: 15.76M
According to Acticor Biotech SAS latest financial reports and stock price the company's current number of shares outstanding is 15.76M. At the end of December 2022 the company had 10.55M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Acticor Biotech SAS (ALACT) from 2010 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 15.76M 30.55%
2023 12.07M 14.44%
2022 10.55M 35.54%
2021 7.78M 22.37%
2020 6.36M 21.38%
2019 5.24M 70.67%
2018 3.07M -7.38%
2017 3.31M 0.00%
2016 3.31M 0.00%
2015 3.31M 0.00%
2014 3.31M 0.00%
2013 3.31M 0.71%
2012 3.29M 0.00%
2011 3.29M -34.01%
2010 4.99M 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 1,511.53%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M 294.70%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 2,939.70%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 2,413.45%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH